Pioglitazone after Ischemic Stroke or Transient Ischemic Attack

Cited by (1,110)

Items 301–400 of 1,110

1. The Aggressive Diabetic Kidney Disease in Youth-Onset Type 2 Diabetes: Pathogenetic Mechanisms and Potential Therapies
   Michela Amatruda, Guido Gembillo, Alfio Edoardo Giuffrida, Domenico Santoro, Giovanni Conti · 2021 · Medicina
2. The association between triglyceride-glucose index combined with obesity indicators and stroke risk: A longitudinal study based on CHARLS data
   Weicai Liang, Haichun Ouyang · 2024 · BMC Endocrine Disorders
3. The dark side of browning
   Kirstin A. Tamucci, Maria Namwanje, Lihong Fan, Li Qiang · 2017 · Protein & Cell
4. Complex interplay among adiposity, insulin resistance and bone health
   Chun‐Ming Ma, Katherine Thuy Trang Tonks, Dorit Samocha‐Bonet, Jerry Richard Greenfield · 2018 · Clinical Obesity
5. Pioglitazone use in patients with diabetes and risk of bladder cancer: a systematic review and meta-analysis
   Huaqing Yan, Haiyun Xie, Yufan Ying, Jiangfeng Li, Xiao Wang, Xin Xu, Xiangyi Zheng · 2018 · Cancer Management and Research
6. Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)
   Giulio Marchesini, Elisabetta Bugianesi, Patrizia Burra, Fabio Marra, Luca Miele, Anna Alisi, Piero Vajro, Mario Masarone, Salvatore Petta, Marcello Persico et al. · 2021 · Nutrition Metabolism and Cardiovascular Diseases
7. Glucagon-like peptide-1 receptor agonists and stroke: A systematic review and meta-analysis of cardiovascular outcome trials
   Anastasia T. Adamou, Fotios Barkas, Haralampos J. Milionis, George Ntaios · 2024 · International Journal of Stroke
8. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus
   Guntram Schernthaner, Marie Helene Schernthaner-Reiter, Gerit-Holger Schernthaner · 2016 · Clinical Therapeutics
9. Diabetes and stroke: An important complication
   Zachary T. Bloomgarden, ROBERT J. CHILTON · 2020 · Journal of Diabetes
10. Perspectives of Antidiabetic Drugs in Diabetes With Coronavirus Infections
    Bao Sun, Shiqiong Huang, Jiecan Zhou · 2021 · Frontiers in Pharmacology
11. Efficacy of lower doses of pioglitazone after stroke or transient ischaemic attack in patients with insulin resistance
    John David Spence, Catherine M. Viscoli, Walter N. Kernan, Lawrence H. Young, Karen L. Furie, Ralph A. DeFronzo, Muhammad A Abdul‐Ghani, Paresh Dandona, Silvio E. Inzucchi · 2022 · Diabetes Obesity and Metabolism
12. Ponatinib treatment promotes arterial thrombosis and hyperactive platelets
    Alona A. Merkulova, Steven C. Mitchell, Evi X. Stavrou, Gabriel L Forbes, Alvin H. Schmaier · 2019 · Blood Advances
13. Microglial V-set and immunoglobulin domain-containing 4 protects against ischemic stroke in mice by suppressing TLR4-regulated inflammatory response
    Qingping Lyu, Xiaojun Pang, Zibin Zhang, Yuyu Wei, Jinxu Hong, Huai Chen · 2019 · Biochemical and Biophysical Research Communications
14. Careful use to minimize adverse events of oral antidiabetic medications in the elderly
    André Jacques Scheen · 2021 · Expert Opinion on Pharmacotherapy
15. Recent Pharmacological Options in Type 2 Diabetes and Synergic Mechanism in Cardiovascular Disease
    Aikaterini Andreadi, Saverio Muscoli, Rojin Tajmir, Marco Meloni, Carolina Muscoli, Sara Ilari, Vincenzo Mollace, David Della‐Morte, Alfonso Bellia, Nicola Di Daniele et al. · 2023 · International Journal of Molecular Sciences
16. Family physician-led, team-based, lifestyle intervention in patients with metabolic syndrome: results of a multicentre feasibility project
    Khursheed N. Jeejeebhoy, Rupinder Dhaliwal, Daren Keith Heyland, Roger Leung, Andrew G. Day, Paula M. Brauer, Dawna Royall, Angelo Tremblay, David M. Mutch, Lew Pliamm et al. · 2017 · CMAJ Open
17. Cardiac Autonomic Neuropathy as a Result of Mild Hypercaloric Challenge in Absence of Signs of Diabetes: Modulation by Antidiabetic Drugs
    Ola Al‐Assi, Rana Ghali, Ali Mroueh, Abdullah Kaplan, Nahed Mougharbil, Ali Hussein Eid, Fouad Anthony Zouein, Ahmed Fawzy EL‐Yazbi · 2018 · Oxidative Medicine and Cellular Longevity
18. Dipeptidyl peptidase-4 inhibitors and protection against stroke: A systematic review and meta-analysis
    Fotios Barkas, Moses Elisaf, Vasilis Tsimihodimos, Haralampos J. Milionis · 2016 · Diabetes & Metabolism
19. Pioglitazone and PPAR-γ modulating treatment in hypertensive and type 2 diabetic patients after ischemic stroke: a national cohort study
    Chi‐Hung Liu, Tsong-Hai Lee, Yu‐Sheng Lin, Pi‐Shan Sung, Yi‐Chia Wei, Yanrong Li · 2020 · Cardiovascular Diabetology
20. Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease
    Gregory G. Schwartz, Lawrence A. Leiter, Christie Mitchell Ballantyne, Philip J. Barter, Donald M. Black, David G. Kallend, Fouzia Laghrissi‐Thode, Eran Leitersdorf, John J.V. McMurray, Stephen James Nicholls et al. · 2020 · Diabetes Care
21. The Many Facets of PPAR-γ Agonism in Obesity and Associated Comorbidities: Benefits, Risks, Challenges, and Future Directions
    Dimitris C. Kounatidis, Natalia G. Vallianou, Eleni Rebelos, Marina Kouveletsou, Paraskevi Kontrafouri, Ioanna Eleftheriadou, Evanthia Diakoumopoulou, Ιrene Karampela, Nikolaοs Tentolouris, Μaria Dalamaga · 2025 · Current Obesity Reports
22. Therapeutic Effects of Targeted PPARɣ Activation on Inflamed High-Risk Plaques Assessed by Serial Optical Imaging In Vivo
    Jah Yeon Choi, Jiheun Ryu, Hyun Jung Kim, Joon Woo Song, Joo Hee Jeon, Dae‐Hee Lee, Dong Joo Oh, Dae‐Gab Gweon, Wang‐Yuhl Oh, Hongki Yoo et al. · 2017 · Theranostics
23. Impact of Visceral Adipose Tissue on Clinical Outcomes After Acute Ischemic Stroke
    Jahae Kim, Kang‐Ho Choi, Kyung Wook Kang, Joon‐Tae Kim, Seong‐Min Choi, Seung‐Han Lee, Man‐Seok Park, Byeong Chae Kim, Myeong‐Kyu Kim, Ki‐Hyun Cho · 2019 · Stroke
24. Pharmacological activation of peroxisome proliferator‐activated receptor γ (PPAR‐γ) protects against hypoxia‐associated fetal growth restriction
    Sydney L. Lane, R. Blair Dodson, Alexandrea S. Doyle, Haemin Park, Hinal Rathi, Christopher J. Matarrazo, LORNA GRINDLAY MOORE, Ramón A. Lorca, Gabriel H. Wolfson, Colleen Glyde Julian · 2019 · The FASEB Journal
25. Ponatinib and other CML Tyrosine Kinase Inhibitors in Thrombosis
    Peng Zeng, Alvin H. Schmaier · 2020 · International Journal of Molecular Sciences
26. Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)
    Giulio Marchesini, Elisabetta Bugianesi, Patrizia Burra, Fabio Marra, Luca Miele, Anna Alisi, Piero Vajro, Mario Masarone, Salvatore Petta, Marcello Persico et al. · 2021 · Digestive and Liver Disease
27. Pioglitazone reduces epicardial fat and improves diastolic function in patients with type 2 diabetes
    Alexander J. Moody, Marjorie Molina‐Wilkins, Geoffrey D. Clarke, Aurora Merovci, Carolina Solis‐Herrera, Eugênio Cersósimo, ROBERT J. CHILTON, Patricia Iozzo, Amalia Gastaldelli, Muhammad A Abdul‐Ghani et al. · 2022 · Diabetes Obesity and Metabolism
28. Prediabetes and macrovascular disease: Review of the association, influence on outcome and effect of treatment
    Kleinherenbrink, W., Osei, E., den Hertog, H.M., Zandbergen, A.A.M. · 2018 · European Journal of Internal Medicine
29. Prevention and treatment of ischaemic and haemorrhagic stroke in people with diabetes mellitus: a focus on glucose control and comorbidities
    Simona Sacco, Matteo Foschi, Raffaele Ornello, Federico De Santis, Riccardo Pofi, Michele Romoli · 2024 · Diabetologia
30. Liraglutide Improves Myocardial Perfusion and Energetics and Exercise Tolerance in Patients With Type 2 Diabetes
    Amrit Chowdhary, Sharmaine Thirunavukarasu, Tobin Joseph, Nicholas Jex, Sindhoora Kotha, Marilena Giannoudi, Henry Procter, Lizette Cash, Sevval Akkaya, David Andrew Broadbent et al. · 2024 · Journal of the American College of Cardiology
31. The Search for Disease-Modifying Therapies in Pulmonary Hypertension
    Chen-­Shan Chen Woodcock, Stephen Y. Chan · 2019 · Journal of Cardiovascular Pharmacology and Therapeutics
32. Management of Diabetes in Candidates for Liver Transplantation and in Transplant Recipients
    Lucia Brodosi, Salvatore Petta, Maria Letizia Petroni, Giulio Marchesini, Maria Cristina Morelli · 2021 · Transplantation
33. An updated meta-analysis of pioglitazone exposure and bladder cancer and comparison to the drug’s effect on cardiovascular disease and non-alcoholic steatohepatitis
    Mayer B. Davidson, Deyu Pan · 2017 · Diabetes Research and Clinical Practice
34. 2020 Consensus of Taiwan Society of Cardiology on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases
    Chern‐En Chiang, Kwo-Chang Ueng, Ting‐Hsing Chao, Tsung‐Hsien Lin, Yih-Jer Wu, Kang-Ling Wang, Shih‐Hsien Sung, Hung‐I Yeh, Yi‐Heng Li, Ping‐Yen Liu et al. · 2020 · Journal of the Chinese Medical Association
35. Association of triglyceride-glucose index with ischemic stroke recurrence in nondiabetic patients with small vessel occlusion: a multicenter hospital-based prospective cohort study
    Li Wu, Jinmao Zhu, Chenghao Li, Juehua Zhu, Zheng Dai, Yongjun Jiang · 2022 · Cardiovascular Diabetology
36. The Role of Diabetes, Obesity, and Metabolic Syndrome in Stroke
    Xian Nan Tang, David S. Liebeskind, Amytis Towfighi · 2017 · Seminars in Neurology
37. Evidence-Based Management of Diabetes in Older Adults
    Arshag D. Mooradian · 2018 · Drugs & Aging
38. Stroke prevention
    Clothilde Isabel, David Calvet, Jean‐Louis Mas · 2016 · La Presse Médicale
39. Update on pre-diabetes: Focus on diagnostic criteria and cardiovascular risk
    Antonino Di Pino, Francesca Urbano, Salvatore Piro, Francesco Purrello, Agata Maria Rabuazzo · 2016 · World Journal of Diabetes
40. Upregulation of miR-1306-5p decreases cerebral ischemia/reperfusion injury in vitro by targeting BIK
    Xuelin Chen, Caixia Li, Jianghao Li, Luoping Sheng, Xianglu Liu · 2019 · Bioscience Biotechnology and Biochemistry
41. Worsening baroreflex sensitivity on progression to type 2 diabetes: localized vs. systemic inflammation and role of antidiabetic therapy
    Nour‐Mounira Z. Bakkar, Nahed Mougharbil, Ali Mroueh, Abdullah Kaplan, Ali Hussein Eid, Souha A. Fares, Fouad Anthony Zouein, Ahmed Fawzy EL‐Yazbi · 2020 · American Journal of Physiology-Endocrinology and Metabolism
42. The Influence of Anti-Diabetic Drugs on Prostate Cancer
    Miłosz Knura, Wojciech Garczorz, Adam Borek, Franciszek Drzymała, Krystian Rachwał, Kurian George, Tomasz Francuz · 2021 · Cancers
43. Triglyceride-glucose index predicts death in patients with stroke younger than 65
    Ruishan Liu, Lijuan Li, Lu Wang, Shihong Zhang · 2023 · Frontiers in Neurology
44. Decrease of cardiovascular risk in patients with type 2 diabetes: review of the common strategies and clinical studies
    В. В. Салухов, Yurii Sh. Khalimov, Шустов Сергей Борисович, D V Kadin · 2018 · Diabetes Mellitus
45. Multi-Target Neuroprotection of Thiazolidinediones on Alzheimer’s Disease via Neuroinflammation and Ferroptosis
    Jiahui Yang, Xiaohua Shi, Yingying Wang, Ming Ma, Hongyu Liu, Jiaoqi Wang, Zhongxin Xu · 2023 · Journal of Alzheimer s Disease
46. Shifting Paradigms in the Medical Management of Type 2 Diabetes: Reflections on Recent Cardiovascular Outcome Trials
    Faramarz Ismail‐Beigi, Etie S. Moghissi, Mikhail Kosiborod, Silvio E. Inzucchi · 2017 · Journal of General Internal Medicine
47. Treatment with the PPARγ Agonist Pioglitazone in the Early Post-ischemia Phase Inhibits Pro-inflammatory Responses and Promotes Neurogenesis Via the Activation of Innate- and Bone Marrow-Derived Stem Cells in Rats
    T. Kinouchi, Keiko T. Kitazato, Kenji Shimada, Kenji Yagi, Yoshiteru Tada, Nobuhisa Matsushita, Yoshitaka Kurashiki, Junichiro Satomi, Masataka Sata, Shinji Nagahiro · 2017 · Translational Stroke Research
48. PPARγ Deacetylation Confers the Antiatherogenic Effect and Improves Endothelial Function in Diabetes Treatment
    Longhua Liu, Lihong Fan, Michelle Chan, Michael James Kraakman, Jing Liang Yang, Yong Fan, Nicole Aaron, Qianfen Wan, Maria Alícia Carrillo-Sepúlveda, Alan R. Tall et al. · 2020 · Diabetes
49. Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα) in the Metabolic Syndrome: Is Pemafibrate Light at the End of the Tunnel?
    Jean‐Charles Fruchart, Michel Paul Hermans, Jamila Fruchart‐Najib, Tatsuhiko Kodama · 2021 · Current Atherosclerosis Reports
50. Treatment options for nonalcoholic steatohepatitis - a safety evaluation
    Danny Issa, Julia J. Wattacheril, Arun Jayant Sanyal · 2017 · Expert Opinion on Drug Safety
51. Type 2 diabetes mellitus
    Melanie Jane Davies, Soo Kyung Lim, Tommy Slater, Jonathan Goldney, Athena Philis‐Tsimikas, Denise R. Franco, Roberta Lamptey, Thomas E. Yates, Tsvetalina I. Tankova, Ildiko Lingvay · 2026 · Nature Reviews Disease Primers
52. Cardiovascular benefits of the newer medications for treating type 2 diabetes mellitus
    Srikanth Yandrapalli, Wilbert S. Aronow · 2017 · Journal of Thoracic Disease
53. The VGVAPG Peptide Regulates the Production of Nitric Oxide Synthases and Reactive Oxygen Species in Mouse Astrocyte Cells In Vitro
    Konrad A. Szychowski, Jan Gmiński · 2019 · Neurochemical Research
54. Calcification biomarkers and vascular dysfunction in obesity and type 2 diabetes: influence of oral hypoglycemic agents
    Francesca Schinzari, Manfredi Tesauro, Aldo Bertoli, Alessia Valentini, Augusto Veneziani, Umberto Campia, Carmine Cardillo · 2019 · American Journal of Physiology-Endocrinology and Metabolism
55. Chinese Herbs and Repurposing Old Drugs as Therapeutic Agents in the Regulation of Oxidative Stress and Inflammation in Pulmonary Diseases
    Chien-Chung Yang, Chuen‐Mao Yang · 2021 · Journal of Inflammation Research
56. Non-alcoholic fatty liver disease: Current therapeutic options
    Avik Majumdar, Jef Verbeek, Emmanuel A. Tsochatzis · 2021 · Current Opinion in Pharmacology
57. Clinical pharmacology of antidiabetic drugs: What can be expected of their use?
    André Jacques Scheen · 2022 · La Presse Médicale
58. Inhibition of the sodium-glucose co-transporter 2 in the elderly: clinical and mechanistic insights into safety and efficacy
    Riobaldo M.R. Cintra, Filipe A. Moura, Luiz Sérgio Fernandes de Carvalho, Joaquim Barreto, Marcos Antônio Tambascia, Roberto Pecoits‐Filho, Andrei Carvalho Sposito · 2019 · Revista da Associação Médica Brasileira
59. Effect of pioglitazone in acute ischemic stroke patients with diabetes mellitus: a nested case–control study
    Min-Hee Woo, Hye Sun Lee, Jinkwon Kim · 2019 · Cardiovascular Diabetology
60. Triglyceride-glucose index, symptomatic intracranial artery stenosis and recurrence risk in minor stroke patients with hypertension
    Yongle Wang, Tingting Liu, Yanan Li, Kaili Zhang, Haimei Fan, Jing Li Ren, Juan Li, Yali Li, Xinyi Li, Xuemei Wu et al. · 2023 · Cardiovascular Diabetology
61. Insulin Resistance and a Long, Strange Trip
    Clay F. Semenkovich · 2016 · New England Journal of Medicine
62. Newly Discovered Abnormal Glucose Tolerance in Patients With Acute Myocardial Infarction and Cardiovascular Outcomes: A Meta-analysis
    Nitchakarn Laichuthai, Muhammad A Abdul‐Ghani, Mikhail Kosiborod, Wasita Warachit Parksook, Stephen John Kerr, Ralph Anthony DeFronzo · 2020 · Diabetes Care
63. Incident ischaemic stroke and Type 2 diabetes: trends in incidence and case fatality in Scotland 2004–2013
    Stephanie H. Read, David McAllister, Helen Martina Colhoun, Bassam Farran, Colin Fischbacher, J.J. Kerssens, Graham Leese, Robert S. Lindsay, Rory J. McCrimmon, Stuart J. McGurnaghan et al. · 2017 · Diabetic Medicine
64. Effects of Lobeglitazone, a Novel Thiazolidinedione, on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus over 52 Weeks
    Soo Kyung Lim, Kyoung Min Kim, Sin Gon Kim, Doo Man Kim, Jeong‐Taek Woo, Choon Hee Chung, Kyung Soo Ko, Jeong Hyun Park, Yongsoo Park, Sang Jin Kim et al. · 2017 · Diabetes & Metabolism Journal
65. Insulin Resistance and Insulin Handling in Chronic Kidney Disease
    Vishnu P. Parvathareddy, Jiao Wu, Sandhya S. Thomas · 2023 · Comprehensive physiology
66. Targeting Pioglitazone Hydrochloride Therapy After Stroke or Transient Ischemic Attack According to Pretreatment Risk for Stroke or Myocardial Infarction
    Walter N. Kernan, Catherine M. Viscoli, Jennifer L. Dearborn, David M. Kent, ROBIN A. CONWIT, Pierre B. Fayad, Karen L. Furie, Mark Gorman, Peter Guarino, Silvio E. Inzucchi et al. · 2017 · JAMA Neurology
67. Residual cardiovascular risk among people with diabetes
    Satya Dash, Lawrence A. Leiter · 2019 · Diabetes Obesity and Metabolism
68. Rosiglitazone has a neutral effect on the risk of dementia in type 2 diabetes patients
    Chin‐Hsiao Tseng · 2019 · Aging
69. 5 Conservative treatment for PAD – Risk factor management
    Ulrich Frank, Sigrid Nikol, J. J. F. Belch · 2019 · VASA
70. Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus
    Ipsen, Emil Ørskov, Madsen, Kasper S, Chi, Yuan, Pedersen-Bjergaard, Ulrik, Richter, Bernd, Metzendorf, Maria-Inti, Hemmingsen, Bianca · 2020 · Cochrane Database of Systematic Reviews
71. Emerging therapies for right ventricular dysfunction and failure
    Anna Klinke, Torben Schubert, Marion Müller, Ekaterina Legchenko, Jason G.E. Zelt, Tsukasa Shimauchi, Lars Christian Napp, Alexander M.K. Rothman, Sébastien Bonnet, Duncan John Stewart et al. · 2020 · Cardiovascular Diagnosis and Therapy
72. Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes
    Brian Tomlinson, Miao Hu, Yuzhen Zhang, Paul Chan, Zhong-Min Liu · 2016 · Expert Opinion on Drug Metabolism & Toxicology
73. Insulin Resistance and Insulin Handling in Chronic Kidney Disease
    Vishnu P. Parvathareddy, Jiao Wu, Sandhya S. Thomas · 2023 · Comprehensive physiology
74. Posttransplant diabetes mellitus: recent developments in pharmacological management of hyperglycemia
    Munoz Pena, Juan M, Cusi, Kenneth · 2023 · The Journal of Clinical Endocrinology & Metabolism
75. Strategies for Diabetes Management: Using Newer Oral Combination Therapies Early in the Disease
    Joel Zonszein, Per‐Henrik Groop · 2016 · Diabetes Therapy
76. Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver disease
    Emanuel Raschi, Arianna Mazzotti, Elisabetta Poluzzi, Fabrizio De Ponti, Giulio Marchesini · 2018 · Expert Opinion on Pharmacotherapy
77. Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes
    Garry, Elizabeth M., Buse, John B., Lund, Jennifer L., Pate, Virginia, Stürmer, Til · 2018 · Diabetes, Obesity and Metabolism
78. Novel Cardiometabolic Medications in the Cardiovascular-Kidney-Metabolic Syndrome Era
    Neal Pohlman, Prem N Patel, Utibe R. Essien, Jingjing Tang, Joshua J. Joseph · 2025 · The Journal of Clinical Endocrinology & Metabolism
79. Clinical Care Pathway for the Risk Stratification and Management of Patients With Metabolic Dysfunction–Associated Steatotic Liver Disease
    Fasiha Kanwal, Fernando Bril, Vincent Wai‐Sun Wong, Leon A. Adams, Kim M. Pfotenhauer, NEIL SKOLNIK, Eugene E. Wright, Robert H. Eckel, Mazen Noureddin, Rohit Seth Loomba et al. · 2026 · Gastroenterology
80. Pharmacological management of type 2 diabetes: what’s new in 2017?
    André Jacques Scheen · 2017 · Expert Review of Clinical Pharmacology
81. Thiazolidinediones and Glucagon‐Like Peptide‐1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study
    Judith de Ruijter-van Dalem, Johanna H. M. Driessen, Andrea Michelle Burden, Coen D.A. Stehouwer, Olaf H. Klungel, Frank de Vries, Martijn C.G.J. Brouwers · 2021 · Hepatology
82. Risk of cardiovascular events associated with pathophysiological phenotypes of type 2 diabetes
    Jacob Volmer Stidsen, Diana Hedevang Christensen, Jan Erik Henriksen, Kurt Højlund, Michael Hecht Olsen, Reimar Wernich Thomsen, Lotte Brix Christensen, Jens Steen Nielsen, Thomas Bastholm Olesen, Henning Beck‐Nielsen · 2022 · European Journal of Endocrinology
83. Diabetes as one of the long-term COVID-19 complications: from the potential reason of more diabetic patients’ susceptibility to COVID-19 to the possible caution of future global diabetes tsunami
    Yasamin Sharbatdar, Ronak Mousaviyan, Seyed Mostafa Noorbakhsh Varnosfaderani, Fatemeh Aziziyan, Mahsa Liaghat, Payam Baziyar, Ali Yousefi Rad, Chanour Tavakol, Amir Mansour Moeini, Mohsen Nabi‐Afjadi et al. · 2023 · Inflammopharmacology
84. Is Coronary Artery Disease Inevitable in Type 2 Diabetes? From a Glucocentric to a Holistic View on Patient Management
    Giulia Ferrannini, Anna Norhammar, Viveca Gyberg, Linda Mellbin, Lars Rydén · 2020 · Diabetes Care
85. A multicentre, double‐blind, placebo‐controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add‐on therapy in type 2 diabetic patients treated with metformin and dapagliflozin
    Soo Kyung Lim, Seung‐Hwan Lee, Kyung‐Wan Min, Chang Beom Lee, Sang Yong Kim, Hye Jin Yoo, Nan Hee Kim, Jae Hyeon Kim, Seungjoon Oh, Jong Chul Won et al. · 2024 · Diabetes Obesity and Metabolism
86. Impaired glucose metabolism and the risk of vascular events and mortality after ischemic stroke: A systematic review and meta-analysis
    Nurcennet Kaynak, Valentin Kennel, Torsten Rackoll, Daniel Schulze, Matthias Endres, Alexander H. Nave · 2024 · Cardiovascular Diabetology
87. Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective
    Peter Lindsay Thompson, Timothy M. E. Davis · 2016 · Clinical Therapeutics
88. Impact of treatment with pioglitazone on stroke outcomes: A real‐world database analysis
    Christopher Ll. Morgan, Silvio E. Inzucchi, Jorge Puelles, Sara Jenkins‐Jones, Craig J. Currie · 2018 · Diabetes Obesity and Metabolism
89. Current Status and Potential Therapeutic Strategies for Using Non-coding RNA to Treat Diabetic Cardiomyopathy
    Amit K. Rai, Brooke Lee, Ramesh Gomez, Deepu Rajendran, Mahmood Khan, Venkata Naga Srikanth Garikipati · 2021 · Frontiers in Physiology
90. Therapy of Type 2 Diabetes in Patients with SARS-CoV-2 Infection
    Weronika Bielka, Agnieszka Przezak, Andrzej Pawlik · 2021 · International Journal of Molecular Sciences
91. Telmisartan use and risk of dementia in type 2 diabetes patients with hypertension: A population-based cohort study
    Chi‐Hung Liu, Pi‐Shan Sung, Yanrong Li, Wen‐Kuan Huang, Tay-Wey Lee, Chin‐Chang Huang, Tsong‐Hai Lee, Tien‐Hsing Chen, Yi‐Chia Wei · 2021 · PLoS Medicine
92. Efficacy of antihyperglycemic therapies on cardiovascular and heart failure outcomes: an updated meta-analysis and meta-regression analysis of 35 randomized cardiovascular outcome trials
    Masashi Hasebe, Satoshi Yoshiji, Yamato Keidai, Hiroto Minamino, Takaaki Murakami, Daisuke Tanaka, Yoshihito Fujita, Norio Harada, Akihiro Hamasaki, Nobuya Inagaki · 2023 · Cardiovascular Diabetology
93. PPARγ in Atherosclerotic Endothelial Dysfunction: Regulatory Compounds and PTMs
    Jinwen Luan, Xiaohui Ji, Longhua Liu · 2023 · International Journal of Molecular Sciences
94. Dual-trajectory of TyG levels and lifestyle scores and their associations with ischemic stroke in a non-diabetic population: a cohort study
    Hui Zhou, Xiong Ding, Yulong Lan · 2024 · Cardiovascular Diabetology
95. Treatment of Type 2 Diabetes: From “Guidelines” to “Position Statements” and Back
    Ofri Mosenzon, Rena M. Pollack, Itamar Raz · 2016 · Diabetes Care
96. Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium–glucose co-transporter 2 inhibitors
    Dario Rahelić, Eugen Javor, Tomo Lucijanić, Marko Skelin · 2016 · Annals of Medicine
97. The Infamous, Famous Sulfonylureas and Cardiovascular Safety: Much Ado About Nothing?
    Laurentiu M. Pop, Ildiko Lingvay · 2017 · Current Diabetes Reports
98. 2018 consensus of the Taiwan Society of Cardiology and the Diabetes Association of Republic of China (Taiwan) on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases
    Chern‐En Chiang, Shih-Yi Lin, Tsung‐Hsien Lin, Tzung‐Dau Wang, Hung‐I Yeh, Jung‐Fu Chen, Chia‐Ti Tsai, Yi-Jen Hung, Yi‐Heng Li, Ping‐Yen Liu et al. · 2018 · Journal of the Chinese Medical Association
99. Serum levels of omentin-1 association with early diagnosis, lesion volume and severity of acute ischemic stroke
    Jun-Yan Yue, Jie Chen, Qingwu Wu, Xiaohuan Liu, Meixia Li, Zheng Li, Yanjun Gao · 2018 · Cytokine
100. Oral antidiabetes agents for the management of inpatient hyperglycaemia: so far, yet so close
     Theocharis Koufakis, Omar G. Mustafa, Pantelis E Zebekakis, Kalliopi Kotsa · 2020 · Diabetic Medicine